EGFR and ovarian cancer: Activated PKG I also inhibited ovarian cancer proliferation (Fig. 2A), invasion (Fig. 2B), and metastasis (Fig. 2C) in the absence of EGFR activation, but the effect was less significant than that of EGF-stimulated therapy.